South & Central America Cell Therapy CDMO Market Analysis and Forecast by Size, Share, Growth, Trends 2025-2031

The South & Central America Cell Therapy CDMO Market size is expected to reach US$ 403.7 Million by 2031 from US$ 105.0 Million in 2024. The market is estimated to record a CAGR of 21.3% from 2025 to 2031.

Executive Summary and South & Central America Cell Therapy CDMO Market Analysis:

The cell therapy CDMO market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. Increasing investments in biotechnology and regenerative medicine, coupled with the rising prevalence of chronic and genetic diseases, are fueling demand for cell-based therapies. Improved regulatory frameworks and government initiatives support innovation and local manufacturing, making it attractive for CDMOs. Additionally, partnerships between global pharmaceutical companies and local CDMOs are expanding production capabilities, reducing costs, and accelerating time-to-market. Surging awareness among healthcare professionals and patients about the benefits of personalized therapies, along with advancements in scalable manufacturing technologies, contributes to market expansion. The region’s cost-effective labor and operational advantages attract foreign investments, positioning South & Central America as a promising hub for cell therapy development and production.

South & Central America Cell Therapy CDMO Market: Strategic Insights

South & Central America Cell Therapy CDMO Market Segmentation Analysis:

• By Service Type, the South & Central America Cell Therapy CDMO Market is segmented into Drug Development and Manufacturing, Testing and Regulatory Services, and Other Service Types. The Drug Development and Manufacturing segment dominated the market in 2024.
• By End User, the South & Central America Cell Therapy CDMO Market is segmented into Pharmaceutical Companies, Biopharmaceutical Companies, and Other End Users. The Biopharmaceutical Companies segment dominated the market in 2024.

South & Central America Cell Therapy CDMO Market Players Density: Understanding Its Impact on Business Dynamics

The South & Central America Cell Therapy CDMO Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

South & Central America Cell Therapy CDMO Market Outlook

The increasing integration of AI and digital transformation is enabling CDMOs to overcome traditional manufacturing challenges, such as variability, scalability, and regulatory compliance, through automation, predictive analytics, and real-time optimization.

WuXi Advanced Therapies deployed AI-driven digital twin systems in 2025 to simulate and optimize cell culture and viral production processes, reducing variability in ex vivo gene-modified therapies. Thermo Fisher Scientific introduced the Gibco CTS DynaCellect in 2024 for automated T-cell selection, minimizing manual handling and contamination risks. Lonza Group expanded allogeneic cell therapy production using closed-system automation for scalable delivery. Cellares' Cell Shuttle employs robotic AI systems for autologous cell therapy, enhancing process efficiency. Amgen leverages AI platforms such as AWS SageMaker for drug design and automated manufacturing controls. Novartis and Roche invest in AI for CAR-T processing, accelerating personalized treatments.

AI-driven tools enable real-time process optimization. Thermo Fisher Scientific utilizes AI for automated visual inspections in biologics manufacturing, thereby reducing false rejects and improving yields in sterile environments that are critical for cell therapies. Similarly, GBI Biomanufacturing employs predictive analytics for equipment monitoring, achieving a 20% reduction in downtime and supporting bioreactor optimization for cell culturing. These applications result in 20-30% faster batch processing and 15-25% better equipment utilization across CDMOs.

Digital twins simulate cell therapy processes for virtual testing

In supply chain orchestration, SAP's Cell and Gene Therapy Orchestration platform automates data exchanges between sponsors and CDMOs, slashing integration lead times from 30 minutes to under 1 minute. This trend fosters decentralized models and point-of-care manufacturing, improving accessibility and consistency in cell therapies. Lonza (with its Cocoon platform) and Ori Biotech automate workflows, digitizing data for AI-enhanced oversight and reducing batch failure rates. These trends mitigate risks, accelerate development, and improve patient-specific outcomes, positioning CDMOs as strategic innovators in cell therapy

South & Central America Cell Therapy CDMO Market Country Insights

By country, the South & Central America Cell Therapy CDMO Market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil held the largest share in 2024.

In Brazil, the burden of diseases treatable by cell therapy remains significant, with cancer leading as a key target. According to GLOBOCAN 2022 estimates from the International Agency for Research on Cancer (IARC), there were 627,193 new cancer cases and 278,835 deaths. Among these, leukemia accounted for 11,859 new cases and 8,790 deaths, non-Hodgkin lymphoma for 11,093 new cases and 5,372 deaths, and multiple myeloma for 5,757 new cases and 4,397 deaths, underscoring the need for advanced therapies, such as CAR-T cells. The demand for cell therapies in Brazil is driven by the country’s large patient population and the high prevalence of genetic disorders. According to a 2021 study, "Medical Genetics Workforce in Brazil: Practitioners, Services, and Disease Distribution," ~53,746 live births were with rare genetic diseases. Additionally, the 2022 study, "The Brazilian Rare Genomes Project," reported that approximately 13.2 million people in Brazil were affected by rare diseases.

Recent developments show progress toward local production and accessibility. ANVISA has streamlined regulatory oversight for clinical trials and registrations, enabling institutions such as Instituto Butantan and Fiocruz to advance CAR-T and stem cell therapies. In 2024, Brazil launched domestic CAR-T manufacturing initiatives, including the first Latin American production unit at Nutera-Nucleo de Terapia Celular in Sao Paulo, developed by Butantan and Hemocentro Ribeirão Preto using proprietary lentiviral vectors. Approvals include Luxturna in 2020 for retinal dystrophy and Roctavian in 2024 for hemophilia A.

Partnerships, such as Terumo Blood & Cell Technologies' expansion of automated systems, including Quantum Flex in 2024, have boosted manufacturing capacity. Public funding reached about US$ 45 million from 2020 to 2024 for advanced therapy R&D, with ongoing trials at Hospital Israelita Albert Einstein and UNICAMP focusing on leukemia and lymphoma. Companies such as Eurofarma—a Brazilian multinational biopharmaceutical corporation—have expanded their operations to include the production of cell therapies. Eurofarma's strategic investments in research and development, along with its extensive product portfolio, underscore the involvement of domestic companies in the advanced therapy space. In July 2022, Boston CRO acquired Rio de Janeiro-based Instituto Brasil de Pesquisa Clinica (IBPClin), marking its first step toward implementing a decentralized clinical trial model in Latin America. The organization reports having conducted over 160 industry-sponsored studies, enrolling more than 7,000 participants across 12 Brazilian states.

Sao Paulo’s Instituto Butantan plays a key role in advancing the CDMO sector. Renowned for its expertise in immunobiology and biopharmaceuticals, the institute’s initiatives support the development of cell and gene therapies. Partnerships between such institutions and CDMOs strengthen Brazil’s capabilities in advanced therapy research and manufacturing.

South & Central America Cell Therapy CDMO Market Company Profiles

Some of the key players operating in the market include Thermo Fisher Scientific Inc, Charles River Laboratories International Inc, Catalent Inc, Lonza Group AG, WuXi Biologics Inc, Takara Bio Inc, FUJIFILM Holdings Corp, AGC Biologics AS, National Resilience Inc, and SK Pharmteco Inc.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

South & Central America Cell Therapy CDMO Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise